Tradestie Institutional Equity Comparison Engine

DERM vs EDGE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DERM Overall Edge

DERM Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Journey Medical Corporation Common Stock (DERM) driven by superior Valuation, Growth & Margin while EDGE counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, DERM trades at 8.3x Forward P/E with -2.9% operating margin (+7.6% YoY revenue) versus EDGE at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, DERM sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against EDGE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner DERM
DERM 8.3x vs EDGE N/M Fwd P/E
Growth & Margin Winner DERM
Op Margin -2.9% vs N/A ยท YoY +7.6% vs N/A
Momentum & Technical Winner EDGE
1Y -56.9% vs +3.6% ยท 52W Pos 1% vs 35%
Options & Structure Winner EDGE
BREAKDOWN (4th %ile IV) vs UNCLASSIFIED (N/A IV)
DERM NASDAQ
Journey Medical Corporation Common Stock
Pharmaceutical Preparations
$3.30
-7.04% 1D
Market Cap $100.2M
1M Return -35.17%
1Y Return -56.86%
Forward P/E 8.3x
Unified AI Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 72.0 Mom 59.0
EDGE US Equity
EDGE
Institutional Equity
$46.01
-4.8% 1D
Market Cap N/A
1M Return -11.47%
1Y Return +3.56%
Forward P/E N/M
Unified AI Score
43.7 / 100 HOLD
Tech 28.0 Fund 48.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DERM -56.86% EDGE +3.56% Spread: +62.96 pp (EDGE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DERM TTM Op. Margin: -2.9% EDGE TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DERM vs EDGE. Trailing 12-month operating profitability (DERM -2.9% vs EDGE N/A) and valuation multiples (DERM 8.3x vs EDGE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DERM (7) vs EDGE (3)
Institutional Metric DERM EDGE Criterion Row Winner
Market Capitalization Scale $100.2M N/A Larger Scale DERM
Trailing P/E Ratio Valuation 17.6x N/M Lower Multiple DERM
Forward P/E Ratio Valuation 8.3x N/M Lower Multiple DERM
Revenue Growth (YoY) Growth +7.6% N/A Higher Growth DERM
Operating Margin (TTM) Profitability -2.9% N/A Higher Margin DERM
Net Profit Margin Profitability -7.3% N/A Higher Margin DERM
Return on Equity (ROE) Capital Efficiency -17.6% N/A Higher ROE DERM
52-Week Range Position Momentum 1% ($3โ€“$10) 35% ($42โ€“$53) Stronger Trend EDGE
Beta / 30D Volatility Risk Regime 2.08ฮฒ ยท 77% Vol 0.98ฮฒ ยท 27% Vol Lower Realized Risk EDGE
Unified Institutional Score Composite Signal 40.9 / 100 (SELL) 43.7 / 100 (HOLD) Higher Composite EDGE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DERM vs EDGE Buy Guide
DERM BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live DERM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EDGE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EDGE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DERM nor EDGE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.